67MO Neoadjuvant and adjuvant toripalimab in high-risk locoregionally advanced nasopharyngeal carcinoma: A randomised, double-blind, placebo-controlled, phase II trial
Immuno-Oncology and Technology(2023)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要